Publications & Posters
Scholarly publications
Immuno-Oncology
SRK-181
June 2021
2021 American Society of Clinical Oncology (ASCO) Annual Meeting
First-in-Human Phase 1 Trial (DRAGON) of SRK-181: A Potential First-in-Class Selective Latent TGFβ1 Inhibitor, Alone or in Combination with Anti-PD-(L)1 Treatment in Patients with Advanced Solid Tumors
Spinal Muscular Atrophy
Apitegromab
May 2021
16th International Congress on Neuromuscular Diseases (ICNMD 2021)
TOPAZ: Phase 2 Study Evaluating Efficacy and Safety of Apitegromab in Later-Onset Spinal Muscular Atrophy; An Interim Analysis
Spinal Muscular Atrophy
Apitegromab
May 2021
Advances in Therapy
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
Spinal Muscular Atrophy
Apitegromab
April 2021
2021 Virtual American Academy of Neurology (AAN) Annual Meeting
A Phase 2 Study to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ): Interim Analysis Results
Immuno-Oncology
SRK-181
April 2021
American Association for Cancer Research (AACR) Annual Meeting 2021
Development of a Comprehensive Biomarker Strategy to Support the Latent TGFβ1 Inhibitor SRK-181 Phase 1 Clinical Trial, DRAGON
Immuno-Oncology
SRK-181
March 2021
International Journal of Toxicology
